<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: ASH 2008 &#8211; Actimid-Dexamethasone Combination Highly Effective In Treating Relapsed And Refractory Multiple Myeloma</title>
	<atom:link href="http://www.myelomabeacon.com/news/2008/12/09/ash-2008-pomalidomide-dexamethasone-combination-highly-effective-in-treating-relapsed-or-refractory-multiple-myeloma/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.myelomabeacon.com/news/2008/12/09/ash-2008-pomalidomide-dexamethasone-combination-highly-effective-in-treating-relapsed-or-refractory-multiple-myeloma/</link>
	<description>Multiple myeloma news, resources, and online forums for patients, caregivers, and others interested in multiple myeloma.</description>
	<lastBuildDate>Sat, 11 Feb 2012 16:45:23 +0000</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	
	<item>
		<title>By: Jessica Langholtz</title>
		<link>http://www.myelomabeacon.com/news/2008/12/09/ash-2008-pomalidomide-dexamethasone-combination-highly-effective-in-treating-relapsed-or-refractory-multiple-myeloma/comment-page-1/#comment-2022</link>
		<dc:creator>Jessica Langholtz</dc:creator>
		<pubDate>Sat, 26 Dec 2009 21:07:13 +0000</pubDate>
		<guid isPermaLink="false">http://www.myelomabeacon.com/?p=7436#comment-2022</guid>
		<description>Dear Janice,

Actimid (pomalidomide) is still undergoing Phase 2 clinical trials for evaluation of its safety and efficacy for the treatment of multiple myeloma. A timeline has not yet been announced to indicate when Celgene, it’s manufacturer, will apply for FDA approval. We will keep you posted at The Myeloma Beacon when more information becomes known.

Best,
Jessica Langholtz</description>
		<content:encoded><![CDATA[<p>Dear Janice,</p>
<p>Actimid (pomalidomide) is still undergoing Phase 2 clinical trials for evaluation of its safety and efficacy for the treatment of multiple myeloma. A timeline has not yet been announced to indicate when Celgene, it’s manufacturer, will apply for FDA approval. We will keep you posted at The Myeloma Beacon when more information becomes known.</p>
<p>Best,<br />
Jessica Langholtz</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: janice schmeeckle</title>
		<link>http://www.myelomabeacon.com/news/2008/12/09/ash-2008-pomalidomide-dexamethasone-combination-highly-effective-in-treating-relapsed-or-refractory-multiple-myeloma/comment-page-1/#comment-1859</link>
		<dc:creator>janice schmeeckle</dc:creator>
		<pubDate>Wed, 23 Dec 2009 23:25:29 +0000</pubDate>
		<guid isPermaLink="false">http://www.myelomabeacon.com/?p=7436#comment-1859</guid>
		<description>My comment seems to have gotten lost or removed, so I will ask again.  Can we be given any idea of they will seek FDA approval for Pomalidomide?  We have been following the trials for Pomalidomide for over two years, with high hopes that it would be FDA approved. It could be of great help for many myeloma patients.

Thank you,
Janice</description>
		<content:encoded><![CDATA[<p>My comment seems to have gotten lost or removed, so I will ask again.  Can we be given any idea of they will seek FDA approval for Pomalidomide?  We have been following the trials for Pomalidomide for over two years, with high hopes that it would be FDA approved. It could be of great help for many myeloma patients.</p>
<p>Thank you,<br />
Janice</p>
]]></content:encoded>
	</item>
</channel>
</rss>

